Food and Drug Law Journal Publishes Akin Gump Article on State Regulations and the FDA

September 26, 2016

Reading Time : 1 min

Contact:

Jacinta O'Shea-Ramdeholl

Director of Communications

Sarah Richmond

Senior Communications Manager

Nathan Brown, a partner in the health practice at Akin Gump, and Eli Tomar, an associate in the public and policy practice, have written the article “Could State Regulations be the Next Frontier in Preemption Jurisprudence?” which was published in Food and Drug Law Journal.

The article begins with an analysis of the history of state regulation of FDA-regulated industries and the expansion of the FDA’s jurisdiction. Brown and Tomar then explain federal exemption in the context of FDA law and offer a way to understand “the overlap between federal and state authorities.”

After providing some examples “of existing or proposed state requirements that would potentially interfere with the federal regulatory regime for outsourcing facilities,” the article concludes by offering “preliminary suggestions for properly balancing federal and state oversight in order best to protect the public health.”

To read the full article, please click here.

Share This Insight

People Mentioned in This News

© 2024 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.